Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
DYN Stock Chart & Stats
$16.15
-$0.74(-3.10%)
At close: 4:00 PM EST
$16.15
-$0.74(-3.10%)
Day’s Range― - ―
52-Week Range$6.36 - $25.00
Previous CloseN/A
Volume117.44K
Average Volume (3M)1.80M
Market Cap
$2.61B
Enterprise Value$1.78B
Total Cash (Recent Filing)$791.89M
Total Debt (Recent Filing)$120.47M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Apr 30, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding161,805,160
10 Day Avg. Volume1,767,971
30 Day Avg. Volume1,796,420
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.10
Forecast
1Y Price Target
$41.29Price Target Upside155.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FORCE Platform Clinical ValidationThe DELIVER registrational expansion met its primary endpoint with increased dystrophin expression, providing clinical validation of Dyne’s FORCE delivery technology. This durable evidence supports platform credibility across programs and strengthens the company’s ability to advance multiple candidates toward registration and commercialization.
Near-term Regulatory/commercial PathA defined path to seek U.S. Accelerated Approval and a potential commercial launch within a ~12-month window materially shortens the timeline to revenue generation for z-rostudirsen. This near-term regulatory plan concentrates development resources but, if realized, converts clinical progress into sustainable commercial operations and partnerships.
Extended Cash Runway And Low LeverageAn ending cash position of roughly $1.1B, supplemented by an upsized $350M offering, provides a multi-year runway into early 2028 and lowers immediate financing pressure. Combined with very low debt-to-equity, this financial flexibility supports continued R&D, registrational trials, and initial commercial investments through key regulatory milestones.
Bears Say
Pre-revenue CompanyDyne remains entirely pre-revenue across multiple years, meaning long-term value depends on successful clinical development and commercialization of first products. The absence of product sales leaves the business reliant on milestones and external funding rather than operating cash flow, elevating execution and funding risk over the medium term.
Widening Losses And Accelerating Cash BurnLosses and cash burn have widened materially, with 2025 operating and free cash flows deeply negative. Sustained heavy R&D and clinical costs increase the need for capital raises and create dilution risk. If execution timelines slip or trials expand, burn could accelerate further, pressuring the durability of the current runway.
High Dependence On Positive Regulatory OutcomesThe company’s path to commercialization is highly binary, hinging on regulatory approval for lead programs. While a validated platform reduces technical risk, business success depends on favorable FDA decisions and subsequent uptake. Regulatory setbacks would materially delay revenue and likely require additional financing rounds.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $6.36 and its highest was $25.00 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $2.61B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 58 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Mar 02, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.763 by $0.003.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 161,805,160 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.763. Following the earnings report the stock price went up 3.393%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.29 (155.64% Upside)
$41.29 (155.64% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.60%
12-Months-Change
Fundamentals
Return on Equity
-60.66%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
DYN Stock 12 Month Forecast
Average Price Target
$41.29
▲(155.64% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---